文献速递慢性肾脏病水电解质与酸碱

VALOR-CKD研究设计与人群:一项多中心、随机、双盲、安慰剂对照试验,评估veverimer延缓代谢性酸中毒慢性肾脏病患者疾病进展的有效性和安全性

Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

VALOR-CKD是一项国际多中心随机双盲安慰剂对照试验,纳入血清碳酸氢盐12-20 mmol/L且eGFR 20-40 mL/min/1.73 m²的代谢性酸中毒合并慢性肾脏病患者,每日一次口服veverimer,主要终点为肾脏病进展(终末期肾病、eGFR较基线持续下降>40%或肾衰竭死亡)。2018年12月至2021年12月共随机1480例,基线平均年龄65.1岁,女性42%,平均eGFR 29.1 mL/min/1.73 m²,平均血清碳酸氢盐17.5 mmol/L。

要点

  • 纳入标准为血清碳酸氢盐12-20 mmol/L且eGFR 20-40 mL/min/1.73 m²的代谢性酸中毒合并CKD患者。
  • 主要终点为肾脏病进展:终末期肾病、eGFR较基线持续下降>40%或肾衰竭死亡。
  • 共随机1480例,基线平均eGFR 29.1 mL/min/1.73 m²,中位5年预测肾衰竭风险32%。

核心结论

  • VALOR-CKD已招募大量代谢性酸中毒且CKD进展高风险人群,以确定veverimer对进行性肾功能丧失风险的影响。

研究设计与样本

  • VALOR-CKD为国际、随机、多中心、双盲、安慰剂对照研究,评估每日一次veverimer对代谢性酸中毒合并CKD患者肾脏病进展的影响。
  • 2018年12月至2021年12月共随机1480例参与者。

主要发现

  • 基线平均年龄65.1岁,女性占42%。
  • 基线平均eGFR为29.1 mL/min/1.73 m²,平均血清碳酸氢盐为17.5 mmol/L。
  • 筛选时中位尿白蛋白与肌酐比值为201 mg/g,中位5年预测肾衰竭风险为32%。
  • 糖尿病和高血压分别见于56%和98%的参与者。

关键数值与推荐

  • 入选标准包括血清碳酸氢盐12-20 mmol/L和eGFR 20-40 mL/min/1.73 m²。
  • 主要终点定义为发生终末期肾病、eGFR较基线持续下降>40%或肾衰竭死亡。
  • 关键次要终点包括对躯体功能的影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether treating metabolic acidosis slows progression of chronic kidney disease (CKD) has not been established. Veverimer is a novel hydrochloric acid binder that removes acid from the gastrointestinal tract leading to an increase in serum bicarbonate; it is being developed to treat metabolic acidosis with the goal of slowing progression of CKD. METHODS: The VALOR-CKD trial is an international, randomized, multicenter, double-blind, placebo-controlled study designed to evaluate the effect of once-daily veverimer on kidney disease progression in patients with metabolic acidosis and CKD. Eligibility criteria include a serum bicarbonate in the range of 12-20 mmol/L and an estimated glomerular filtration rate (eGFR) of 20-40 mL/min/1.73 m2. The primary outcome is kidney disease progression defined as the development of end-stage kidney disease, a sustained decline in eGFR of >40% from baseline or death due to kidney failure. Key secondary endpoints include effects on physical function. RESULTS: Between December 2018 and December 2021, 1480 participants were randomized. The mean age at baseline was 65.1 years and 42% of the patients were female. The mean baseline eGFR was 29.1 mL/min/1.73 m2 and mean serum bicarbonate was 17.5 mmol/L. The median urine albumin-to-creatinine ratio at screening was 201 mg/g and the median 5-year predicted risk of kidney failure was 32%. Diabetes and hypertension were present in 56% and 98% of participants, respectively. CONCLUSIONS: VALOR-CKD has recruited a large population of people with metabolic acidosis at high risk for CKD progression to determine the effects of veverimer on the risk of progressive loss of kidney function.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Mathur VS, Bushinsky DA, Inker L, et al. Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis. Nephrol Dial Transplant. 2023. PMID: 36331426. doi:10.1093/ndt/gfac289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。